Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

THERANEXUS announces the formation of its scientific Board

Download PDF File (375 Ko)

THERANEXUS to present new data on neuron-glia interactions at two scientific events

Download PDF File (380 Ko)

THERANEXUS announces issuance of Chinese patent covering its drug candidate THN102

Download PDF File (381 Ko)

THERANEXUS provides 2018 full-year results and update on activities

Download PDF File (416 Ko)

THERANEXUS announces research collaboration with IRISA using artificial intelligence technologies to enhance therapeutic targeting of neuroglial interactions

Download PDF File (376 Ko)

THERANEXUS to present new scientific data on drug candidate THN201 at AD/PD 2019, the 14th conference on Alzheimer's and Parkinson's diseases

Download PDF File (377 Ko)

THERANEXUS announces preliminary results of phase II trial of THN102 on narcolepsy patients

Download PDF File (296 Ko)

THERANEXUS reports cash position as of 31 December 2018 and provides update on current status of activities

Download PDF File (395 Ko)

THERANEXUS set to receive €6.2 million in funding from the French Investments for the
Future program, managed by Bpifrance, for the development of Neurolead,
its new lead generation platform targeting neuro-glia interactions

Download PDF File

Theranexus announces appointment of Jérôme Martinez to its Board of Directors
Download PDF File (370 Ko)